Drug discovery and development in the pharmaceutical industry.
The discovery and development of new anticancer drugs is a complex and largely empirical process. New compounds can be discovered by screening, modification of existing compounds, rational drug design, and serendipitous basic research observations. Selection of compounds for clinical trials depends on assays of uncertain predictive value. In the pharmaceutical industry, priorities for development of potentially active entities are set and available resources allocated based on the availability and cost of supplies, patent status, potential spectrum of activity, ability to meet regulatory requirements, and market assessments. Competition for resources also occurs from noncancer drugs, eg, cardiovascular agents. Clinical development (testing and approval for commercial distribution) requires close attention to the requirements of national regulatory agencies such as the United States Food and Drug Administration. The arbitrary nature by which compounds with antitumor potential are chosen for development means that some that would be useful never reach clinical trial and others are never made generally available. This article reviews the decision making process in the pharmaceutical industry by which compounds are identified and selected for clinical trial, the regulations in the United States that govern such trials, and what is required to have the drug approved for commercial distribution.
Schacter
L P
LP
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06443.
Anderson
C
C
Canetta
R M
RM
Kelley
S
S
Nicaise
C
C
Onetto
N
N
Rozencweig
M
M
Smaldone
L
L
Winograd
B
B
D000818:Animals; D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D015507:Drugs, Investigational; D006801:Humans; D014481:United States
D000970:Antineoplastic Agents; D015507:Drugs, Investigational